Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-10-29

FDA Approved: DEFLAZACORT ORAL SUSPENSION — Supplemental Application (Cranbury Pharmaceuticals, LLC)

View source ↗

Summary

The FDA approved a supplemental application for Deflazacort oral suspension by Cranbury Pharmaceuticals, expanding the availability of deflazacort in oral suspe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • DEFLAZACORT ORAL SUSPENSION (deflazacort)

Snippet

SUPPL AP for DEFLAZACORT ORAL SUSPENSION (DEFLAZACORT ORAL)